Engineered T Cell Therapy for Cancer in the Clinic

Paper

Abstract

T cells play a key role in cell-mediated immunity, and strategies to genetically modify T cells, including chimeric antigen receptor (CAR) T cell therapy and T cell receptor (TCR) T cell therapy, have achieved substantial advances in the treatment of malignant tumors. In clinical trials, CAR-T cell and TCR-T cell therapies have produced encouraging clinical outcomes, thereby demonstrating their therapeutic potential in mitigating tumor development. This article summarizes the current applications of CAR-T cell and TCR-T cell therapies in clinical trials worldwide. It is predicted that genetically engineered T cell immunotherapies will become safe, well-tolerated, and effective therapeutics and bring hope to cancer patients.

Analysis

Paper intelligence

Summary

This paper reviews the current clinical applications of CAR-T and TCR-T cell therapies for cancer treatment, highlighting their therapeutic potential and future outlook.

Key findings

CAR-T and TCR-T cell therapies have shown substantial advances in treating malignant tumors.
Clinical trials demonstrate encouraging outcomes for CAR-T and TCR-T cell therapies.
Genetically engineered T cell immunotherapies are predicted to become safe, well-tolerated, and effective.

Methods

Review of current applications of CAR-T cell and TCR-T cell therapies in clinical trials worldwide.

Applications

Treatment of malignant tumors.
Cancer treatment.

Confidence100%

Discovery

Related papers

2027PubMed

Nucleofection-Based CRISPR/Cas Delivery in Human T Cells for Immunotherapy Applications.

Ortiz-Bueno M; Millán-López A; Labun K; Benabdellah K

Jan 1, 2027Methods in molecular biology (Clifton, N.J.)

2027PubMed

Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer.

Wu T; Lv B; Wang H; He G; Fu Y; Ji X; Zeng Y; Ni D; Qiu J; Hua K

Jan 1, 2027Bioactive materials

2026arXiv

Combining standard chemoradiotherapy with CAR-T cell therapy in malignant gliomas: Insights from an impulsive mathematical framework and virtual trials

Dmitry Sinelshchikov; Nikols Amaru Mora Millán; Miguel Perales-Patón; Juan Belmonte-Beitia; Matteo Italia

Sep 30, 2026

2026Crossref0 citations

CAR-Mix cell therapies to treat solid tumors by providing synergistic interaction between engineered macrophages and polyclonal T cells.

Xudong Wang; Jin Zhang

Jun 1, 2026Journal of Clinical Oncology

2026Semantic Scholar0 citations

Integration site analysis in engineered T cell therapies: what we measure, what we miss, and what regulators expect

Deividas Pažėraitis; J. Kupčinskas

Feb 23, 2026Cell and Gene Therapy Insights0 influential

2026PubMed

Oncolytic virus-mediated GPC3 delivery overcomes antigen heterogeneity in hepatocellular carcinoma and enhances GPC3-directed immunotherapy.

Chaurasiya S; Kim SI; Sah P; Zhang Z; Vashi Y; Wu H; Cillis J; Park A; Yang A; Woo Y; Xiong G; Liu J; Zhang H; Wang P; Liu C; Fong Y

Jan 1, 2026Frontiers in immunology

Source record

Publication metadata

Authors: Lijun Zhao; Yu Cao
Published: Oct 11, 2019
Journal or venue: Frontiers in Immunology
DOI: 10.3389/fimmu.2019.02250
Paper type: journal article
Source: Openalex

DOI OpenAlex